PUBLISHER: DelveInsight | PRODUCT CODE: 1128298
PUBLISHER: DelveInsight | PRODUCT CODE: 1128298
"KPL-716 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about KPL-716 for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the KPL-716 for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the KPL-716 for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KPL-716 market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.
Vixarelimab (KPL-716) is an investigational fully-human monoclonal antibody that targets OSMRB, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes vixarelimab to be the only monoclonal antibody in development that targets both pathways simultaneously.
In September 2016, Kiniksa completed the acquisition of certain assets of Biogen under an asset purchase agreement or the Biogen Agreement. Under the Biogen Agreement, Kiniksa is obligated to use commercially reasonable efforts to develop and commercialize the acquired assets and made an upfront payment of USD 11.5 million and a technology transfer payment of USD 0.5 million to Biogen. Also, Kiniksa made a milestone payment of USD 4.0 million during the year ended December 31, 2017, associated with the achievement of a specified clinical milestone event. Kiniksa was also obligated to make future milestone payments for each antibody product that included the acquired assets, or an antibody product, of up to USD 325.0 million in the aggregate upon the achievement of specified milestones.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
KPL-716 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of KPL-716 for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of KPL-716 for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions